No Side Effects
Plant-derived agents, including nutritional supplements
with qualifying good manufacturing principles, pose no
risk of adverse effects. There is no qualifying debate. No
evidence to the contrary exists in medical literature.
Period.

If fact, an overwhelming abundance of published research
confirms that all plant-derived agents, and nutritional
supplements derived from natural plants, actually
performed in a “dose-dependent” manner.

Are there upper limits? Like any food, some nutritional
agents can generate minor effects, such as aggravate
digestion (nausea, diarrhea), activate allergic reactions,
and in rare occasions counteract prescription drug
functionality (eg. omega 3 vs blood thinners). In contrast, a
mulitude of published research documents the synergistic
benefit of nutritional agents when taken with
chemotherapeutic drugs! The drugs are more effective and
delay resistance to the therapy. As with any food, personal
experience and common sense is the best approach. A
spice like curcumin, could potentially cause stomach or
digestive upset. It is reasonable to slowly increase the
amount you consume, or consume with meals.

If taking nutritionals, published research clearly presents
dosing information in relation to the effectiveness of each
agent.

Many human clinical trials translated dosing animal
studies to an equivalent dose for humans. HED (“human
equivalent dose”) established the recommended human
dose scaling for a specific animal tested. The problem: the
conversion of equivalent dose from animal to human was
based upon body surface area, “BSA.” Resulting conversion
factors reduced dosing by factors less than 1/10th the
effective animal dose. For example, conversion of effective dosing in an animal experiment is dramatically reduced when applied to human clinical trials. Failure of human clinical trials for agents that have demonstrated dramatically significant benefit, sadly, have missed great opportunities and must suffer the consequences, the lost opportunity. The truly tragic possibility is the failure of clinical trials for potentially helpful agents (see excerpt below).

“Human Equivalent Dose:” handicapping clinical trials?
“A thorough review of the literature reveals that BSA (body surface area) conversions are based on antiquated science and have little justification in current translational medicine compared to more advanced allometric and physiologically based pharmacokinetic modeling. Misunderstood and misinterpreted use of BSA conversions may have disastrous consequences, including underdosing leading to abandonment of potentially efficacious investigational drugs, and unexpected deadly adverse events.”
Translating dosages from animal models to human
clinical trials—revisiting body surface area scaling, 2015